Drug Shares Jump After News of First American Ebola Case

Shares of pharmaceutical companies that produce experimental Ebola drugs spiked in after-market trading today following news of the first diagnosis of the deadly disease in the United States.

The Centers for Disease Control announced this evening that they had confirmed the first case of an individual being diagnosed with the deadly virus, at a hospital in Texas.

First Ebola Case Diagnosed in U.S. Confirmed by CDC

Face-to-Face With Patients in the Ebola Ward

Shares of Tekmira Pharmaceuticals, one of the three known producers of an Ebola drug, jumped as much as 25 percent to more than $26 per share in after-hours trading on the NASDAQ.

Sarepta Therapeutics, which is also reportedly working on a drug, rose by more then 7 percent to over $22 per share on the NASDAQ.

The case announced by the CDC involved an individual who was recently in Liberia but did not have symptoms when traveling back to the United States on Sept. 19.

Although American Ebola patients have been treated in the United States prior to this diagnosis, they all contracted Ebola in West Africa. Ebola has killed 2,917 people and infected 3,346 others in Africa since the outbreak began in March.

Ebola: What you need to know about the deadly outbreak

What is Ebola? How does it spread? Common questions answered

What is Ebola? How does it spread? Who is at risk? What you need to know